Daytrana in the News

Learn more about Daytrana™ by reviewing the press releases below.

News Releases


June 9, 2008 Press Release Heading: Non-safety-related voluntary recall of a limited portion of DAYTRANA™ (methylphenidate transdermal system) patches announced
September 4, 2007 Shire voluntarily withdraws a limited portion of DAYTRANA™ (methylphenidate transdermal system) patches
October 27, 2006 ADHD Patch Daytrana (methylphenidate transdermal system) Effective in Patients Converted From Oral Long-Acting Methylphenidate
October 26, 2006 Daytrana (methylphenidate transdermal system) Provides Individualized Symptom Management
June 29, 2006 Shire's Daytrana, First Transdermal Medication for Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children, Now Available in Pharmacies
May 25, 2006 Significant ADHD Symptom Control With Shorter Daytrana (methylphenidate transdermal system) Wear Time
May 24, 2006 Positive Study Results for Daytrana (methylphenidate transdermal system) Presented at a Major Medical Meeting
April 6, 2006 Shire's Daytrana Transdermal Patch Approved by FDA for Treatment of ADHD
You can also find additional information about Shire, its corporate history, other products, investor relations and leadership by visiting the Shire corporate site.

To view PDF documents, you must have Adobe® Reader® installed on your computer. If you do not have Adobe Reader, download it from the Adobe Web site.

Get Adobe® Reader®
Adobe and Adobe Reader are registered trademarks of Adobe Systems Incorporated.
 

 

Important Safety Information

Tell your doctor about any heart conditions, including structural abnormalities, your child or a family member may have. Inform your doctor immediately if the child develops symptoms that suggest heart problems, such as chest pain or fainting.

Daytrana should not be used if the child has: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients of Daytrana; glaucoma; discontinued in the last 14 days or is taking a monoamine oxidase inhibitor (MAOI); tics, or family history or diagnosis of Tourette’s syndrome.

Tell your doctor before using Daytrana if the child: is being treated for or has symptoms of depression (e.g. sadness, worthlessness, or hopelessness) or bipolar disorder; has family history of tics; has abnormal thoughts or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell your doctor immediately if the child develops any of these conditions/symptoms while using Daytrana.

In clinical studies, side effects were generally mild to moderate. The most common side effects reported with Daytrana were decreased appetite, sleeplessness, sadness/crying, twitching, weight loss, nausea, vomiting, tics, and affect lability (mood swings). Aggression, new abnormal thoughts/behaviors, mania, and growth suppression have been associated with use of drugs of this type. Tell your doctor if the child has blurred vision while using Daytrana.

Abuse of Daytrana can lead to dependence.

Daytrana should be applied daily to clean, dry skin, which is free of any cuts or irritation. Skin redness or itching is common with Daytrana. Allergic skin rash may occur.

Shire US Inc.
© 2008 Shire US Inc., Wayne, PA 19087-5367, (800) 828-2088. All rights reserved.

Daytrana™ is a trademark of Shire Pharmaceuticals Ireland Limited.

D1196 6/08

This site is strictly intended for U.S. residents and is governed solely by U.S. laws and governmental regulations. Please see our online privacy policy for more information.

While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

Contact Us | Daytrana in the News | Site Map | Unsubscribe